3.

Radiation enhancement ratios of PARP inhibitors for colorectal cancer and non-malignant cell lines

Gene mutation status						Radiation enhancement ratio (P-value)
	BRAF	KRAS	PIK3CA	p53		Olaparib	Rucaparib	Talazoparib
Radiation enhancement ratios were calculated from clonogenic survival assays (normalised, by plating efficiency, for effect of drug alone) and comprise the ratio of radiation dose leading to 1% cell survival to the radiation dose producing 1% survival in the combined treatment. Significance (P ≤ 0.05), displayed by in bold, was calculated by one-way ANOVA, with multiple comparisons of each drug against the DMSO control.
CRC cell lines
RKO	p.V600E	WT	p.H1047R	WT		1.48 (P ≤ 0.05)	1.41 (P ≤ 0.05)	1.71 (P ≤ 0.001)
HT29	p.V600E	WT	WT	R273H		1.44 (P ≤ 0.01)	1.28 (P ≤ 0.001)	1.82 (P ≤ 0.001)
DLD1	WT	G13D	p.E545K	S241F		1.18 (P ≤ 0.01)	1.21 (P ≤ 0.01)	1.92 (P ≤ 0.001)
HT55	WT	WT	WT	R213L		1.21 (ns)	1.31 (P ≤ 0.01)	1.39 (P ≤ 0.01)
C10	WT	WT	WT	G245S		1.12 (ns)	1.18 (ns)	1.48 (P ≤ 0.001)
Colo678	WT	G12D	WT	WT		1.12 (ns)	1.15 (ns)	1.21 (P ≤ 0.001)
Non-malignant cell lines
HFLA	n/a	n/a	n/a	n/a		1.09 (ns)	1.3 (P ≤ 0.05)	1.29 (ns)
MRC5	n/a	n/a	n/a	n/a		1.35 (P ≤ 0.05)	1.34 (P ≤ 0.05)	1.52 (P ≤ 0.01)
RPE	n/a	n/a	n/a	n/a		1.1 (ns)	1.07 (ns)	1.24 (P ≤ 0.01)